VPTDF - Ventripoint and at the Mazankowski Heart Institute to Collaborate to Conduct a World-First Study of the Changes in Cardiac Function during Pregnancy
(TheNewswire)
Toronto, Ontario – TheNewswire –March 1, 2022 - Ventripoint Diagnostics Ltd.(" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) will be supporting a world-first study on maternalcardiovascular changes during pregnancy, which will be conducted atthe Mazankowski Alberta Heart Institute in Edmonton, Alberta,Canada.
Dr. Lisa Hornberger, Principal Investigator of studystated “We are very grateful to Ventripoint for their supportthrough equipment of this exciting research endeavor. We know thatwomen with heart disease, particularly congenital (from birth) heartdisease have an increased risk of poor pregnancy outcomes. This Heart& Stroke Foundation of Canada funded research will explore thecontribution of inadequate heart function (use of Ventripoint) andvascular health and their interaction to adverse pregnancy outcomes.Use of the Ventripoint system will facilitate cardiac functioninvestigations even in women with more challenging heart geometry. Itis anticipated this innovative work will lead to improved strategiesto optimize the cardiovascular health of these mothers leading tohealthier pregnancies and infants.”
Dr. Jonathan Windram, Co-investigator stated “We aregrateful to Ventripoint for their continued support. The Ventripointsystem has been proven to assess ventricular volumes and systolicfunction in patients with a variety of cardiac conditions and we areexcited to have the ability to use this technology within ourstudy.”
Cardiovascular disease complicates 1-4% of pregnanciesand is more common in women with hypertensive disorders, which is theleading cause of maternal death ( Ramlakhan,K.P., Johnson, M.R. & Roos-Hesselink, J.W, 2020). One of the areas of focus for the study will be looking at thevascular and ventricular function in pregnant women withcardiovascular disease.
A combination of vascular measuring techniques andheart assessments will be used to understand ventricular and vascularinteractions in mothers during pregnancy. A study of this nature hasnever been attempted before and will provide fundamental informationon changes in cardiac function during pregnancy.
The VMS+3.0 will be used to perform heart assessmentsin this study and will allow for quick, accurate and repeatmeasurements in this groundbreaking study of women’s health. TheVMS+3.0 is gaining more traction in being used to assess differentheart conditions in specific population groups due to its ease of useand accessibility.
The study is being funded by the Canadian Institutes ofHealth Research (CIHR), which is Canada'sfederal funding agency for health research. CIHR funds approximately one billion dollars each year to support the discoveries and innovations thatimprove health and strengthen the healthcare system.
About the Mazankowski Alberta Heart Institute
The
Mazankowski Alberta Heart Institute is one of theleading cardiac centers in Canada. The Principal Investigator of thestudy, Dr. Lisa Hornberger, was the founder and initial Director ofthe University of Alberta’s Fetal and Neonatal Cardiology Programand the current Section Head of Pediatric Echocardiography.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile and can be used with allultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe and Canada.
For further information, pleasecontact:
Dr. George Adams
519-803-6937
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect", "anticipate", "continue","estimate", "objective", "ongoing","may", "will", "project","should", "believe", "plans","intends'' and similar expressions are intended to identifyforward-looking information or statements. The forward-lookingstatements and information are based on certain key expectations andassumptions made by the Company. Although the Company believes thatthe expectations and assumptions on which such forward-lookingstatements and information are based are reasonable, undue relianceshould not be placed on the forward-looking statements and informationbecause the Company can give no assurance that they will prove to becorrect.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2022 TheNewswire - All rights reserved.